No Data
Kangfeng Biotechnology-B(06922) and Po Medical International Medical Trade (Shanghai) have entered into a distribution agreement for respiratory intervention products.
Kangyuan Biology-B (06922) issued an announcement on July 1, 2024 regarding its trade with Boko International Medical (Shanghai) ...
Express News | Cryofocus Medtech Shanghai - Strategic Collaboration in Respect of Respiratory Intervention Products in Mainland China
Express News | Cryofocus Medtech Shanghai - Business Cooperation With Bsc International Medical Trading (Shanghai) Co
Liu Wei was re-elected as the executive director of Kangrun Bio-B (06922).
Kangyuan Bio-B (06922) announced that at the annual meeting of shareholders, Li Kejian, Zhu Jun and Liu Wei were re-elected as the second...
Uncover the reason behind Kangfeng Bio-B's (06922) market capitalization shrinking by nearly 70% in 5 months
In fact, since the end of last year, good news on Kang Feng Biotech's fundamentals has been released one after another, but judging from the stock price trend, none of this has impressed investors; on the contrary, it has caused the company's stock price to fall to a low point. What exactly is the reason behind this?
CRYOFOCUS-B: ANNUAL REPORT 2023
No Data
